Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desferrioxamine in chronic progressive multiple sclerosis: a pilot study

S G Lynch1, K Peters, S M LeVine

  • 1Department of Neurology, University of Kansas Medical Center, Kansas City 66160, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of the charge asymmetry in top quark pair production in <i>pp</i> collisions at [Formula: see text] using the ATLAS detector.

The European physical journal. C, Particles and fields·2015
Same author

Measurement of [Formula: see text] production with a veto on additional central jet activity in <i>pp</i> collisions at [Formula: see text] TeV using the ATLAS detector.

The European physical journal. C, Particles and fields·2015
Same author

Measurement of the top quark mass with the template method in the [Formula: see text] channel using ATLAS data.

The European physical journal. C, Particles and fields·2015
Same author

Search for heavy neutrinos and right-handed <i>W</i> bosons in events with two leptons and jets in <i>pp</i> collisions at [Formula: see text] with the ATLAS detector.

The European physical journal. C, Particles and fields·2015
Same author

Study of e(+)e(-)→ωχ(cJ) at center of mass energies from 4.21 to 4.42 GeV.

Physical review letters·2015
Same author

Search for Higgs boson pair production in the γγbb[over ¯] final state using pp collision data at sqrt[s]=8  TeV from the ATLAS detector.

Physical review letters·2015

This pilot study found desferroxamine (DFO) to be a well-tolerated treatment option for chronic progressive Multiple Sclerosis patients. Short-term DFO therapy did not cause acute neurological worsening in most participants.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Chronic progressive Multiple Sclerosis (MS) presents significant treatment challenges.
  • Conventional therapies often prove ineffective for progressive MS.
  • Identifying novel therapeutic agents is crucial for managing MS.

Purpose of the Study:

  • To evaluate the safety and tolerability of desferroxamine (DFO) in patients with chronic progressive Multiple Sclerosis.
  • To assess DFO as a potential treatment for this refractory neurological condition.

Main Methods:

  • A pilot study was conducted involving patients with chronic progressive MS.
  • Desferroxamine (DFO) was administered via daily 8-hour subcutaneous infusions.
  • The treatment involved a 7-day course of 2 grams daily, followed by a 7-day course of 1 gram daily.

Related Experiment Videos

Main Results:

  • Eighteen out of 19 participants completed the full 21-gram DFO dosage.
  • No acute neurological status deterioration was observed during DFO administration.
  • Common side effects included local redness at injection sites; one patient experienced transient hearing reduction due to nausea.

Conclusions:

  • Desferroxamine (DFO) appears to be relatively well-tolerated in a short-term treatment course for Multiple Sclerosis patients.
  • The findings support further investigation into DFO's efficacy for chronic progressive MS.
  • DFO represents a potential therapeutic candidate for refractory MS cases.